{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "1487627",
  "DateCompleted": {
    "Year": "1993",
    "Month": "02",
    "Day": "23"
  },
  "DateRevised": {
    "Year": "2013",
    "Month": "11",
    "Day": "21"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0268-1315",
      "JournalIssue": {
        "Volume": "7",
        "Issue": "2",
        "PubDate": {
          "Year": "1992",
          "Month": "Nov"
        }
      },
      "Title": "International clinical psychopharmacology",
      "ISOAbbreviation": "Int Clin Psychopharmacol"
    },
    "ArticleTitle": "Paroxetine in the treatment of melancholia and severe depression.",
    "Pagination": {
      "StartPage": "91",
      "EndPage": "94",
      "MedlinePgn": "91-4"
    },
    "Abstract": {
      "AbstractText": [
        "Meta-analyses of the worldwide paroxetine database assessed the efficacy of this compound in the treatment of both DSM-III defined melancholia and hospitalised patients with severe depression (HAMD > or = 25). The analysis for melancholia included 178 paroxetine treated patients and 66 patients treated with placebo. Paroxetine was significantly superior to placebo in the treatment of melancholia and a clear dose-response relationship was established. The meta-analysis for severely depressed hospitalised patients included 109 paroxetine treated patients and 107 patients treated with a tricyclic/tetracyclic control. Paroxetine and active controls showed comparable efficacy in the treatment of severely depressed hospitalised patients."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Universit\u00e9 de Bordeaux, France."
          }
        ],
        "LastName": "Tignol",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Stoker",
        "ForeName": "M J",
        "Initials": "MJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Dunbar",
        "ForeName": "G C",
        "Initials": "GC"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Meta-Analysis"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Int Clin Psychopharmacol",
    "NlmUniqueID": "8609061",
    "ISSNLinking": "0268-1315"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "41VRH5220H",
      "NameOfSubstance": "Paroxetine"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Depressive Disorder"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Dose-Response Relationship, Drug"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Paroxetine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Psychiatric Status Rating Scales"
    }
  ]
}